Back to simplicity: a four-marker blood cell score to quantify prognostically relevant myeloid cells in melanoma patients.

Veronica HuberLorenza Di GuardoLuca LalliDaniele GiardielloAgata CovaPaola SquarcinaPaola FratiAnna Maria Di GiacomoLorenzo PillaMarcella TazzariChiara CamisaschiFlavio ArientiChiara CastelliMonica RodolfoValeria BerettaMassimo Di NicolaMichele MaioMichele Del VecchioFilippo de BraudLuigi MarianiLicia Rivoltini

Published in: Journal for immunotherapy of cancer (2021)

The MIS >0 identifies melanoma patients with a more aggressive disease, thus acting as a simple blood biomarker that can help tailoring therapeutic choices in real-life oncology.

Keyphrases

end stage renal disease
ejection fraction
induced apoptosis
newly diagnosed
chronic kidney disease
palliative care
prognostic factors
peritoneal dialysis
cell cycle arrest
single cell
bone marrow
dendritic cells
genome wide
stem cells
immune response
dna methylation
oxidative stress
cell death